NCT07265674 2026-01-23
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
Clinical Trials
8 trialsNCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06529718 2025-11-17
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05124002 2024-03-04
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Beijing Tsinghua Chang Gung Hospital
Phase 4 Recruiting
NCT05535647 2022-09-10
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05489692 2022-08-10
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Completed